Skip to main content

Table 3 Cyclin D1 and p27 tumor expression in the pre-treatment setting

From: Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial

Patients completed all study parts n = 42
Cyclin D1 nuclear fraction (n = 30)  
 Negative 2 (7%)
 Low (1-50%) 12 (40%)
 High (51-100%) 16 (53%)
Cyclin D1 nuclear intensity (n = 30)  
 Negative 2 (7%)
 Weak 5 (12%)
 Moderate 14 (33%)
 Strong 9 (30%)
Cyclin D1 cytoplasmic intensity (n = 30)  
 Negative 11(37%)
 Weak 14 (47%)
 Moderate 2 (7%)
 Strong 3 (10%)
p27 nuclear fraction (n = 33)  
 Negative 0
 Low (1-50%) 8 (24%)
 High (51-100%) 25 (76%)
p27 nuclear intensity (n = 33)  
 Negative 0
 Weak 3 (9%)
 Moderate 18 (55%)
 Strong 12 (36%)
p27 cytoplasmic intensity (n = 33)
 Negative 17 (52%)
 Weak 14 (42%)
 Moderate 2 (6%)
 Strong 0